
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
HOOK • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold HOOK in your mock portfolio yet.
Hookipa Pharma’s financial profile is clearly loss‑making, as reflected in its negative EPS and PE ratio. The magnitude of the loss per share (-4.83) versus the current share price suggests the market is heavily discounting the company’s earnings power and/or assigning primarily option value to its pipeline. Without evidence of improving profitability or line‑of‑sight to positive earnings, the financial picture remains weak.
The stock’s recent 5.1% gain over the last month is modest and occurs around a flat long‑term trend, with the price sitting right at its 200‑day moving average. An RSI of 48.45 is essentially neutral, suggesting neither overbought nor oversold conditions. Overall, technicals point to consolidation rather than a clear directional trend.
Alternative data for Hookipa Pharma show limited external traction and muted growth signals. Website traffic is very low, hiring activity is flat at zero openings, and social media followings are small with minimal recent growth. These indicators suggest constrained commercial visibility and limited current scaling activity.
Overall, Hookipa Pharma’s stock profile skews bearish, driven primarily by its deep unprofitability and weak alternative data signals. While the technical picture is neutral and shows some short‑term price improvement, there is little in the current data to suggest a sustained positive re‑rating without fundamental or pipeline catalysts. Until there is clearer evidence of improving financials or stronger external traction, risk remains elevated relative to visible reward.

HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead


HOOKIPA Pharma Inc - FORM 8 (OPD)
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: